||EPS - Basic
||Market Cap (m)
Real-Time news about Huveaux (London Stock Exchange): 0 recent articles
|cerrito: and now 22.05%
No idea filipe google reveals nothing and HVX seems to be the only company where they have a notifiable interest
will try to phone the company to find out
This should be a plus for the share price but apart from a possibility of a corporate action there is nothing to make this move up ie we are not expecting any results or indeed a trading statement in the near future nor is there any major business development expected.|
|psolomons: This seems oversold to me. The company issued a very upbeat trading statement recently after all the trauma earlier in the year and yet the share price is resting at near record lows.
Unless HVX have been misleading the city there should be some re-rating on the way.|
|haroldthegreat: have noticed that a small amount of purchases move the share price by quite a large amount. is this normal?|
|cerrito: Ran through the profit forecast figures, something I did not get round to doing when they came out the first time.
They are talking about H2 EBITDA being £5/6m similar to H2 06 of £5.4.
That of course does not recognize that in H207 they will get full benefit of Letts and Leckie and Leckie acquisitions whereas in H206 they only got partial benefit.
Furthermore in H2 interest costs will be higher than the £674k of H2 06 and more like the £752k of H1 07.
To have a stab at post tax profit for the full year, if you say ebitda is £6m , you double the first half interest figure to give £1.5m, and then double the first half depreciation and amortization to give you £3.7m and say tax is £0.8m you have a breakeven figure.
All pretty back of the envelope but does explain the current share price.
I am neither selling or buying.|
|cerrito: Good to see healthy director buying today.
I guess that has given me more confidence than the figures have.
For all the song and dance of the problems of healthcare in France the decline in learning's ebitda from £926K in the same semester last year to £ 209K was more important in the fall of overall corporate EBITDA from £1780K to £963k.
Also note that Political EBITDA was £195k compared to £603k in the first half of 2005.
I am comfortable with the top ups I have made in the thirties in the last couple of weeks.
That having been said share price progress will be slow. There presumably will be no major acquisitions this year given their share price although they do have a modest borrowing capacity.
For them to reach the consensus forecast of £4.22m they will need to make £5.3m in the second half which will be quite a stretch, especially as there are no signals given of an imminent turn around in healthcare's fortunes. If the Tories' woes continue that will be a downer for Politics especially for the party conference publications but I am hopeful that they will be able to beat the £2m EBITDA of the second half of last year. Education will be key.|
|broomsticks: I hate to admit this but whilst Huveaux claims in its Trading Update of 26 June 2007, RNS Number:04212 that its present problem is "Our Healthcare Division in France has seen a significant drop in sales revenue as compared to the first half of 2006." that is not the reason for my decision to sell some of my shares. I disposed of them when there was a lack of feedback from the MediaFinance 2007 conference. That omission added to what was and still is my unease about the axing of BBC Jam. Not the axing per se because nobody can be pleased that 200 people lost their jobs, it just struck me as odd that the commercial sector had complained about the impact BBC Jam had on their business when the website was perceived by professionals as having basic design errors both technical and educational, as a consequence of which its traffic was minimal. This £150m website was in fact struggling to meet the licence conditions set by the BBC Trust. Further to that it had been criticised by the Content Advisory Board as not complying with its remit. It was from this setup that Andy Ware joined Huveaux.
Another worrying point is that Fenman twice extended its sale.
Letts partnership with TutorVista should prove to be a positive move by Huveaux but I am mindful of the fact that TutorVista is a young company backed by a venture capitalist awash with funds.
Having said all that I intend to hold on to my remaining shares. The present share price makes it tempting to buy back some shares, but..................hmmmm
|jlabrey: It is clear that Epic is driving value across the Group. I was very interested to see the appointment of Andy Ware as the Director of the new Education Division (there are now four business divisions). He is a former director of learning at the BBC.
It seems Huveaux wants to be a consolidator in the education publishing sector, with many companies exiting this space at the moment because they don't want to invest in digitalisation. The revision guides businesses will then become the nucleus of a much bigger division.
The question (and risk) is how any acquistion(s) will be funded going forward. Borrowing is modest but there is probably only another £18m available from this route to maintain prudence. Then it's cash and shares. I would like to see the Group potentially exploring the joint venture model to limit earnings dilution, which could give us a slice of a much more significant market.
On a separate note, I saw that Jane's Information Group was put up for sale last week by their Canadian owners with an expected price tag of £50 million.
On HVX's share price performance, it is disappointing that the market has not spotted the value here but it gives opportunities to add and, hopefully, make bigger gains in the long term... The management seem to be doing all the right things to secure growth.|
Thanks for that I noticed earlier that Reed Elsevier has put its education division up for sale. I haven't looked at the whole sector but see that Huveaux's share price appears to have suffered as a result. It is probably to Reed Elsevier's advantage to sell off its education division, it will certainly have a leaner image after the disposal.
It gives a bad impression of the whole educational sector when companies appear unable to successfully incorporate an educational division within their boundaries of expertise. For me that is where Huveaux differs in that it is able to fully utilise its education division through the astute use of Epic's expertise and flexibility within the fields of blended and e-learning.
If anyone is interested and has some time to listen to Donald Clark the former CEO of Epic Group Plc I have placed some links below. For information Donald Clark has been associated with e-learning for more than 20 years. The following podcasts are interviews of him by Steven Walsh of Kineo. They give some clues to the legacy that Donald Clark has given to Epic and consequently the ethos in which Huveaux operates.
Donald Clark gives his views on the educational value of blogging and why he personally blogs as a means of communication.
|barbra2: could the 300,000 'T' transactions be sales instead of buys?
I think they are - that's why the share price has not moved up despite the large number of buys during the day.
Buyers today have inadvertantly help someone to offload their holding (possibly) Sorry for stating the obvious!
Hope I will be proved wrong as I have also bought today.|
|psolomons: Trouble is if HVX have to pay more for epic because of the interest from futuremedia it will be reflected in a downward move of the HVX share price.
Deal needs to be sorted before any major share price moves. imho.|
Huveaux share price data is direct from the London Stock Exchange